#### Check for updates

#### **OPEN ACCESS**

EDITED BY Cecile Tissot, Clinique des Grangettes, Switzerland

#### REVIEWED BY Saneeha Shahid,

Children's Hospital Colorado, United States Adam Small, New York University, United States

\*CORRESPONDENCE

Ji Wu gxnnwuji@163.com

RECEIVED 11 March 2025 ACCEPTED 20 May 2025 PUBLISHED 04 June 2025

#### CITATION

Wei L, Zeng D, Huang L, Luo X and Wu J (2025) A case report of delayed persistent thirddegree atrioventricular block 7 years after eccentric umbrella occlusion of a perimembranous ventricular septal defect in infancy. Front. Pediatr. 13:1591928. doi: 10.3389/fped.2025.1591928

#### COPYRIGHT

© 2025 Wei, Zeng, Huang, Luo and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# A case report of delayed persistent third-degree atrioventricular block 7 years after eccentric umbrella occlusion of a perimembranous ventricular septal defect in infancy

Lihui Wei<sup>1</sup>, Decai Zeng<sup>1</sup>, Liuliu Huang<sup>2</sup>, Xiangjie Luo<sup>2</sup> and Ji Wu<sup>1\*</sup>

<sup>1</sup>Department of Ultrasonic Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, China, <sup>2</sup>Department of Cardiothoracic Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China

This article reports an 8-year-old female patient who underwent trans-thoracic small-incision interventional Pm-VSD occlusion with an eccentric umbrella (defect diameter 10 mm, occluder waist diameter 12 mm) at 4 months of age (July 2017). Seven years after the operation (October 2024), she gradually developed third-degree atrioventricular block. Despite the removal of the occluder and ventricular septal defect repair combined with steroid pulse therapy, the conduction abnormality persisted. This case, with a 7 - year disease course evolution, provides in - depth insights into the development process of delayed complete atrioventricular block (CAVB) following eccentric umbrella occlusion in infancy and early childhood, particularly for high - risk patients with occlusion adjacent to the conduction system. It also suggests the significance of electrocardiogram monitoring for over 5 years post - operation in such high - risk patients.

#### KEYWORDS

perimembranous ventricular septal defect, trans-thoracic occlusion, eccentric occluder, delayed atrioventricular block, device-related complications

#### Introduction

Ventricular septal defect (VSD) is the most common congenital heart disease (1). Transcatheter occlusion of perimembranous ventricular septal defect (Pm-VSD) is an alternative treatment option with limitations in clinical practice (2). In the occlusion of Pm-VSD, recent studies have suggested that the incidence of early CAVB is approximately 0.3%–2.1%, and the incidence of delayed CAVB is 0.3%–0.46% (3–5). Although the incidence of delayed atrioventricular block (CAVB) is not high, its prognosis is poor. Once it occurs, most patients need to be treated with a pacemaker. This article reports a case of persistent third-degree atrioventricular block 7 years after trans-thoracic small-incision eccentric umbrella occlusion, aiming to emphasize the importance of extending the follow-up period for such patients and timely intervention when necessary.



## Case report

The patient was an 8-year-old female who presented with asymptomatic bradycardia detected during a physical examination. Her medical history showed that she had a congenital perimembranous ventricular septal defect (Pm-VSD), and the preoperative electrocardiogram was normal (Figure 1A). In July 2017 (at 4 months of age), preoperative evaluation showed that the defect diameter was approximately 10 mm, the distance from the tricuspid valve margin was  $\geq 2 \text{ mm}$ , the distance from the aortic valve was <2 mm, and there was no aortic valve regurgitation. Prior to the surgery, a comprehensive assessment was conducted. Genetic testing for genes such as NKX2.5 was performed, and the results showed no mutations. Also, a meticulous examination for syndromic features associated with TBX5 - related disorders was carried out, but no such features were identified. The family expressed concerns over the potential risks and trauma of traditional open - heart surgery, including large incisions, complications during the operation, and long - term impacts on the child's growth. Given the defect's proximity to the aortic valve, the unique structure of the eccentric umbrella provided a better anatomical fit. Additionally, the trans - thoracic minimally - invasive occlusion with this device promised faster postoperative recovery (2), which was vital for the growth and development of the 4-month-old infant. After in - depth discussions with the medical team, the family requested the trans - thoracic small - incision Pm-VSD occlusion using eccentric umbrella. In addition, relevant studies at that time showed that the clinical application of the eccentric umbrella had good results (6-8). An eccentric umbrella with a diameter of 12 mm was finally used to perform transthoracic small-incision Pm-VSD occlusion. After the operation, the patient underwent regular reexaminations. The early electrocardiogram showed a PR interval of 153 ms (Figure 1B), exceeding the normal upper limit (137 ms) for 3-7 month-old females (9, 10), indicating first-degree atrioventricular block, and the ultrasound showed no residual shunt. In November 2023 (the 6th year after the operation), a hospital examination showed a complete right bundle branch block (RBBB) on the electrocardiogram (Figure 2A), and no special treatment was given. In October 2024 (the 7th year after the operation), a slow heart rate of 47 beats per minute was detected during a physical examination, and the electrocardiogram indicated the occurrence of sinus rhythm with 2:1 atrioventricular block (AVB) (Figure 2B). Twenty days later, a reexamination showed progression to third-degree AVB (Figure 2C), and transthoracic echocardiography (TTE) showed significant enlargement of the left atrium and ventricle [left atrial diameter 32 mm (Z value = +3.2), left ventricular end-diastolic diameter 50 mm (Z value = +3.5)], normal systolic function (ejection fraction

Abbreviations

AVB, atrioventricular block, CAVB, complete atrioventricular block, CLBBB, complete left bundle branch block, CRBBB, complete right bundle branch block, ECG, electrocardiogram, Pm-VSD, perimembranous ventricular septal defect, TTE, transthoracic echocardiography, VSD, ventricular septal defect.



64%), mild valvular regurgitation, and a stable occluder position with no residual shunt (Figure 3). Subsequently, the occluder was removed and the VSD was repaired, upon removal, it was found that the occluder had been completely endothelialized and was firmly fixed in the body. Immediately after the operation, methylprednisolone 1 mg/(kg·day) was given to reduce myocardial edema, and intravenous infusion of vitamin C (200 mg/day) and sodium phosphocreatine (2 g/day) was used to nourish the myocardium. The drug treatment lasted for 4 days. In February 2025 (more than 3 months of follow-up), the conduction block had not reversed (Figure 2D). The patient refused permanent pacemaker implantation and is currently under continuous follow-up.

#### Discussion

This case presents a rare delayed complication after transthoracic occlusion of VSD in an infant. The patient was only 4 months old at the time of occlusion, and the VSD was relatively large, with a diameter of 10 mm, was a significant factor. The selected occluder was also relatively large, with a waist diameter of approximately 12 mm (Figure 4). This is consistent with the correlation between VSD diameter, occluder size, and delayed

CAVB reported in previous studies (11). A larger VSD not only indicates more severe structural and hemodynamic issues but also necessitates a larger occluder for closure. Research has shown that VSD diameter is closely linked to the risk of atrioventricular block after occlusion (10). In this case, the 10 mm defect likely led to the use of a 12 - mm occluder, increasing the risk of mechanical compression on the conduction system. Moreover, the aortic - side flange of the eccentric umbrella's proximity to the conduction bundle further raises this risk. For Pm - VSD treatment, surgical closure is a reliable gold standard. But for this 4 - month - old with a large, aortic - valve adjacent Pm - VSD, open - heart surgery had risks like repeated lung infections and extracorporeal - circulation challenges. Considering the family's trauma concerns, trans thoracic small - incision interventional occlusion with an eccentric umbrella was chosen.

The pathological mechanism is likely associated with early mechanical compression [early postoperative PR interval prolonged to 153 ms, exceeding the normal upper limit of 137 ms (10), indicating compression] and progressive fibrosis. The aortic flange of the eccentric umbrella lies in close anatomical proximity to the His bundle, which further exacerbates this risk. As Jin et al. reported, larger occluders relative to the defect size are associated with an increased risk of





Echocardiogram findings 7 years after surgery. (A) Shows the three-dimensional image of the left atrium and ventricle, and (B) shows the apical fourchamber and five-chamber view. The area pointed by the green arrow is the eccentric occluder.



post - implant complications, potentially related to mechanical compression on the conduction system (13). Some studies have also shown that delayed CAVB may be related to device-related inflammatory reactions or endothelial hyperplasia, which can lead to the encapsulation of conduction tissues (14, 15). The aortic-side flange of the eccentric umbrella is closer to the conduction bundle, which may increase this risk. It is worth noting that the patient developed complete right bundle branch block (CRBBB) more than 6 years after the operation, and

gradually progressed to sinus rhythm with 2:1 atrioventricular block (AVB) and finally to third-degree AVB 7 years after the operation. This disease course evolution may be related to the chronic mechanical compression of the conduction system by the eccentric umbrella and the secondary fibrosis process. This suggests that regular electrocardiogram monitoring after occlusion is crucial, even if the patient is asymptomatic, especially in the first year and even more than 5 years after the operation. According to the European Society of Cardiology

Guidelines (2021) (12), if complete left bundle branch block (CLBBB) occurs after occlusion, the occluder should be removed as soon as possible. When CRBBB was detected 6 years after the operation in this case, no special measures were taken, possibly due to insufficient treatment experience. This case further suggests that for patients with the occluder adjacent to the His bundle (especially those who received eccentric umbrella occlusion in infancy), when early conduction bundle abnormalities are detected, timely intervention should be considered, such as removing the occluder and prophylactic pacing, to avoid irreversible damage to the conduction bundle. However, this view still needs to be verified by a large number of clinical studies. In congenital heart disease treatment, the degradable occluder is a new development. It may not suit all patients now but can reduce long - term issues of traditional occluders. Its advantages need more research, and in our paper, we'll focus on its future research potential rather than promoting it as a current alternative. Therefore, in future clinical practice, surgical indications should be more strictly controlled, and appropriate occluders should be selected as much as possible to implement precise treatment. The MemoSorb VSD occluder, launched by Shanghai Shape Memory Alloy Materials Co., Ltd. in 2020, is a fully degradable occluder that can gradually degrade and be absorbed after completing the mission of VSD repair. This feature makes the internal structure of the heart closer to the natural physiological state after the occluder degrades, effectively avoiding a series of complications that may be caused by the long-term retention of nickel-titanium alloy occluders in the body (16). For patients with a defect opening close to the aortic valve (where traditional occluders may compress the conduction bundle after closure and the treatment risk is relatively high), the fully degradable occluder is expected to be a safer treatment option. However, at present, this advantage still needs to be verified by more large-sample and multi-center studies.

## Conclusion

This case exhibits an unusually long interval between trans thoracic Pm - VSD occlusion and the occurrence of CAVB among reported cases in children under 1 year old, which enriches our understanding of the long - term outcomes of such procedures. For high - risk patients with occluders near the conduction system, it implies the importance of extended electrocardiogram monitoring, and the need for more research. It not only emphasizes the necessity of long-term electrocardiogram monitoring but also reveals the potential risks related to the design of the eccentric umbrella. Further research is needed to clarify the predictive factors of delayed conduction abnormalities and optimize the long-term management strategy (especially whether to intervene in a timely manner when subtle conduction bundle abnormalities are detected). This case serves as a wake-up call for clinicians to conduct long-term follow-up of such patients and provides an important reference for continuously exploring the field of congenital heart disease treatment to improve patient prognosis and safety.

## Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

#### **Ethics statement**

The studies involving humans were approved by First Affiliated Hospital of Guangxi Medical University Ethical Review Committee Approval Notice. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation in this study was provided by the participants' legal guardians/next of kin. Written informed consent was obtained from the minor(s)' legal guardian/next of kin for the publication of any potentially identifiable images or data included in this article.

## Author contributions

LW: Writing – original draft. DZ: Conceptualization, Supervision, Writing – original draft, Writing – review & editing. LH: Conceptualization, Writing – original draft, Writing – review & editing. XL: Investigation, Writing – original draft, Writing – review & editing. JW: Writing – original draft, Writing – review & editing.

## Funding

The author(s) declare that financial support was received for the research and/or publication of this article. This study was funded by the Key Program of Guangxi Natural Science Foundation (grant No. 2022JJD140147), the National Clinical Key Specialty Construction Project of China (Department of Cardiovascular Surgery, The First Affiliated Hospital of Guangxi Medical University), and the Clinical Key Specialty Construction Project of Guangxi (Department of Cardiothoracic Surgery, The First Affiliated Hospital of Guangxi Medical University).

## Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## Generative AI statement

The authors declare that no Generative AI was used in the creation of this manuscript.

#### Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

#### References

1. Mitchell SC, Korones SB, Berendes HW. Congenital heart disease in 56,109 births incidence and natural history. *Circulation*. (1971) 43:323–32. doi: 10.1161/01.CIR.43.3. 323

2. Yang J. Transcatheter versus surgical closure of perimembranous ventricular septal defects in children: a randomized controlled trial. J Am Coll Cardiol. (2014) 63(12):1159–68. doi: 10.1016/j.jacc.2014.01.008

3. Bai Y, Xu X-D, Li C-Y, Zhu J-Q, Wu H, Chen S-P, et al. Complete atrioventricular block after percutaneous device closure of perimembranous ventricular septal defect: a single-center experience on 1,046 cases. *Heart Rhythm.* (2015) 12:2132–40. doi: 10.1016/j.hrthm.2015.05.014

4. Jiang D, Han B, Zhao L, Yi Y, Zhang J, Fan Y, et al. Transcatheter device closure of perimembranous and intracristal ventricular septal defects in children: mediumand long-term results. *JAHA*. (2021) 10:e020417. doi: 10.1161/JAHA.120.020417

5. Elmarsafawy H, Hafez M, Alsawah GA, Bakr A, Rakha S. Long-term outcomes of percutaneous closure of ventricular septal defects in children using different devices: a single centre experience from Egypt. *BMC Pediatr.* (2023) 23:381. doi: 10.1186/s12887-023-04194-9

6. Hu X, Peng B. Asymmetric occluder occlusion of outlet ventricular septal defect via a subaxillary approach. *Ann Thorac Surg.* (2021) 112:1532–6. doi: 10.1016/j. athoracsur.2020.07.079

7. Chen F, Li P, Liu S, Du H, Zhang B, Jin X, et al. Transcatheter closure of intracristal ventricular septal defect with mild aortic cusp prolapse using zero eccentricity ventricular septal defect occluder. *Circ J.* (2015) 79:2162–8. doi: 10. 1253/circj.CJ-15-0301

8. Thanopoulos BD, Tsaousis GS, Karanasios E, Eleftherakis NG, Paphitis C. Transcatheter closure of perimembranous ventricular septal defects with the amplatzer asymmetric ventricular septal defect occluder: preliminary experience in children. *Heart.* (2003) 89(8):918–22. doi: 10.1136/heart.89.8.918

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

9. Davignon A, Rautaharju P, Boisselle E, Soumis F, Mégélas M, Choquette A. Normal ECG standards for infants and children. *Pediatr Cardiol.* (1980) 1:123–31. doi: 10.1007/BF02083144

10. Lue H-C, Wu M-H, Wang J-K, Lin M-T, Lu C-W, Chiu S-N, et al. Normal ECG standards and percentile charts for infants, children and adolescents. *Pediatr Neonatol.* (2023) 64:256–73. doi: 10.1016/j.pedneo.2022.07.013

11. Lin L, Liu J, Guo X, Chen H, Huang Y, Zheng H, et al. Risk factors for atrioventricular block after occlusion for perimembranous ventricular septal defect. *Heart Rhythm.* (2022) 19:389–96. doi: 10.1016/j.hrthm.2021.11.027

12. Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. *Eur Heart J.* (2021) 42(35):3427–520. doi: 10.1093/eurheartj/ehab364

13. Jin Y, Han B, Zhang J, Zhuang J, Yan J, Wang Y. Postimplant complications with transcatheter closure of congenital perimembranous ventricular septal defects: a single-center, longitudinal study from 2002 to 2011. *Catheter Cardiovasc Interv.* (2013) 81:666–73. doi: 10.1002/ccd.24638

14. Mertens L, Meyns B, Gewillig M. Device fracture and severe tricuspid regurgitation after percutaneous closure of perimembranous ventricular septal defect: a case report. *Catheter Cardiovasc Interv.* (2007) 70:749–53. doi: 10.1002/ccd.21198

15. Foth R, Quentin T, Michel-Behnke I, Vogt M, Kriebel T, Kreischer A, et al. Immunohistochemical characterization of neotissues and tissue reactions to septal defect–occlusion devices. *Circ Cardiovasc Interv.* (2009) 2:90–6. doi: 10.1161/ CIRCINTERVENTIONS.108.810507

16. Guo G, Hu J, Wang F, Fu D, Luo R, Zhang F, et al. A fully degradable transcatheter ventricular septal defect occluder: towards rapid occlusion and post-regeneration absorption. *Biomaterials.* (2022) 291:121909. doi: 10.1016/j. biomaterials.2022.121909